Assess safety & effectiveness in achieving patency of target venous lesion through 12 months post stent placement, in patients with obstruction of the iliofemoral venous outflow tract.
Prospective, multi-center (22 sites in the US and Europe) single arm, non-randomized.
Key Inclusion Criteria
Unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof
- ≥50% reduction in target vessel lumen diameter (venogram) Clinically significant venous obstruction defined as: CEAP “C” ≥3 OR VCSS Pain ≥2
VIRTUS Clinical Trial |?Efficacy Results
Primary patency rate at 12 months post-intervention
- Freedom from occlusion by thrombosis
- Freedom from surgical or endovascular intervention on target vessel which are found to have re-stenosis or stent occlusion to maintain patency
- Freedom from in-stent stenosis more than 50% by venogram
Primary endpoint was met2
Primary patency rate exceeded the performance goal of 72.1% (p<0.0001)3,4
VIRTUS Clinical Trial | 12-Month Results
98.8% freedom from MAEs through 30 days
Primary endpoint was met2:
Safety rate exceeded the performance goal of 94%5
- VIRTUS demonstrated a clinically meaningful 4.4 decrease in the VCSS score from baseline out to 12 months.
- Vici shifted patients with a severe VCSS score from almost 66% down to 27%,and increased the patients in the mild VCSS score 4-fold.
- 84% of patients experienced VCSS improvement.
VIRTUS Clinical Trial | Conclusions
VIRTUS primary safety and effectiveness endpoints successfully met:
Patient sample with challenging characteristics
Subscribe now to receive venous stent updates.
Get to know more
From expert opinions to fact sheets, find what you need to help educate your patients.